

Grant Funding Agreement for the Conditional Gift (“Funding”) and Terms

Grant Project: Directed evolution of adeno-associated virus (AAV) capsids for effective gene delivery to the muscle fibro-adipogenic progenitors (FAPS)

Grant Funders: Cure CMD, Noelia Foundation (“Grant Funders”)

Funding and Reporting

1. Funding may not be applied to any indirect costs.
2. Funding is committed and will be disbursed as follows:
 - a. \$50,000.00, funded in payments of \$12,500.00, every six months, for two years.
 - b. The initial round of Funding will be paid upon execution of this Agreement by all parties.
3. Use of funds may begin after the agreed-upon personnel required to perform the proposed experiments (as applicable: postdoctoral fellows, graduate students, or technicians) have been recruited and are available to start work.
4. A progress report and update from the principal investigator is required every six months. The report will be sent via email to grants@curecmd.org by the principal investigator. The update should include a brief narrative report and/or no more than five slides with a concise description of the experiments performed and preliminary results obtained since the previous update. The update will also consist of a one-hour video conference call between the principal investigator, relevant personnel in the principal investigator’s laboratory, and Cure CMD’s Scientific Director. The conference call will be scheduled by Cure CMD at least two weeks in advance, at a mutually agreeable time. A progress report and update are considered confidential information of the National Institutes of Neurological Disorders and Stroke (“NINDS”), part of the National Institutes of Health (“NIH”). Any NINDS confidential information which is orally disclosed during a conference call will be reduced to writing and marked “Confidential” by the principal investigator. Grant Funders will not share any unpublished confidential NINDS data with other laboratories or individuals and will not seek inventorship or authorship of any sort.
5. A financial status report—a summary record of withdrawals and deposits for the award account—is required from the NINDS every six months during the grant period. The report will be sent via email to grants@curecmd.org by the NINDS’ financial officer. The report must be submitted for review prior to the NINDS receiving the next Funding payment.
6. The principal investigator agrees to submit publication reprints to the Grant Funders as they are available.

Collaboration and Acknowledgement

7. It is understood that NINDS and the principal investigator intend to comply with the spirit of the Funding. If applicable to the research project partially supported by Funding, the principal investigator may collaborate with other laboratories and, the Grant Funders may introduce the principal investigator to other laboratories, as applicable. In the context of such collaborations, NINDS may share, under appropriate agreements, data and materials, such as constructs, vectors, animal models, cell lines, biomarkers, hybridomas, chemical compounds, etc., generated using Funding, without waiting for publication, as appropriate. Notwithstanding the foregoing, the conduct of NINDS and the principal investigator shall at all times be governed by applicable Federal laws, regulations, and policies.
8. NINDS agrees to publicly acknowledge funding from the Grant Funders, Cure CMD and Noelia Foundation, with support from The Noa Project, in all applicable resulting publications, conference abstracts, presentations and other similar reference materials.

Licensing and Data Sharing

9. NINDS is an agency of the U.S. Federal Government and shall at all times be governed by applicable Federal laws, regulations, and policies, and must remain in control of government-owned intellectual property, including patenting and licensing decisions. Principal investigator, is obligated per Executive Order 10096 to assign all rights in inventions to the U.S. Federal Government and that oversight, including subsequent licensing, of any government-owned inventions is controlled by 35 USC 202-212 and 37 CFR 404.
10. To further extend resource sharing policies, the principal investigator is expected to include, as appropriate, in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using Funding ("Plan") so that other researchers can benefit from these resources, or state appropriate reasons for why such sharing is restricted or not possible. The Grant Funders agree that the Plan must be consistent with applicable laws, regulations and NIH policies, and acknowledges that the basic research mission of NIH includes sharing with third parties for further research any research resources made in whole or in part with NIH funding. Following publication, NINDS may make available the unique model organism research resources generated under the Plan. It is understood and agreed that if the unique model organism research resources generated under the Plan are the subject of a pending patent application or a patent or were created using a patent-pending or patented material or technology, the parties may agree to restrict distribution or freely distribute them.

Institution Information*



a cure is among us

Funded Institution Name:	National Institute of Neurological Disorders and Stroke, National Institutes of Health
Financial Officer Name:	Christine Lam, Budget Officer, NINDS
Financial Officer Email:	lamch@ninds.nih.gov
Financial Officer Telephone:	301-496-4927



a cure is among us

**National Institute of Neurological
Disorders and Stroke, NIH**

Grant Funders

<p>Read and Understood <u>Carsten Bönnemann, MD</u> Principal Investigator Name</p> <hr/> <p>Principal Investigator Signature</p> <hr/> <p>Principal Investigator Signature Date</p>	<p><u>Gustavo Dziewczapolski, PhD</u> Cure CMD Scientific Director</p> <hr/> <p>Cure CMD Scientific Director Signature</p> <hr/> <p>Cure CMD Scientific Director Signature Date</p>
<p>Accepted and Agreed on behalf of NINDS <u>Dr. Walter Koroshetz, NINDS Director</u></p> <hr/> <p>NINDS Representative Signature</p> <hr/> <p>NINDS Representative Signature Date</p>	<p><u>Rachel Alvarez</u> Cure CMD Executive Director Secretary, Board of Directors</p> <hr/> <p>Cure CMD Executive Director Signature</p> <hr/> <p>Cure CMD Executive Director Signature Date</p>
	<p><u>Noelia Canela</u> Noelia Foundation President</p> <hr/> <p>Noelia Foundation President Signature</p> <hr/> <p>Noelia Foundation President Signature Date</p>